New hope for PBC patients: experimental drug CS0159 enters Mid-Stage trial
NCT ID NCT05896124
First seen Mar 19, 2026 · Last updated May 23, 2026 · Updated 8 times
Summary
This study tests an experimental drug called CS0159 in 75 adults with primary biliary cholangitis (PBC), a chronic liver disease. The goal is to see if the drug is safe and can improve liver health markers like ALP levels. Participants receive either CS0159 or a placebo for 12 weeks, followed by an open-label period. This is not a cure, but aims to better control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY BILIARY CHOLANGITIS (PBC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Friendship Hospital, Capitai Medical University
Beijing, Beijing Municipality, 100050, China
-
Beijing Youan Hospital, Capital Medical University
Beijing, Beijing Municipality, 100069, China
-
Henan Provincial People's Hospital
Zhengzhou, Henan, China
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730, China
-
Qilu Hospital of Shandong University
Jinan, Shandong, China
-
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200120, China
-
Shaoyifu Hospital of Zhejiang University Medical
Hangzhou, Zhejiang, 310000, China
-
The Fifth Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangzhou, China
-
The First Affiliated Hospital of USTC Anhui Provincial Hospital
Hefei, Anhui, 230001, China
-
The First Affiliated Hospital,Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
-
The First Bethune Hospital of Jilin University
Changchun, Jilin, China
-
The Seconed Xiangya Hospital of Central South University
Changsha, Hunan, 410011, China
-
The Third Affiliated Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, 510630, China
-
The Third People's Hospital of Zhenjiang
Zhenjiang, Jiangsu, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, China
-
Wuhan Union Hospital of China
Wuhan, Hubei, 430022, China
Conditions
Explore the condition pages connected to this study.